Dastouri F.,National Center for Immunisation and Surveillance of Vaccine Preventable Diseases |
Dastouri F.,University of Sydney |
Hosseini A.M.,Kerman Medical University |
Haworth E.,University of Oxford |
And 7 more authors.
Infectious Disorders - Drug Targets
This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy. © 2014 Bentham Science Publishers B.V. All rights reserved. Source